Rafael Holdings, Inc.
About Rafael Holdings, Inc.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $30.0K
- Net income
- -$30.5M
- Total assets
- $114.1M
- Market cap
- $80.6M
- Operating margin
- -3179.8%
- Net margin
- -3341.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $917.0K
- Operating expenses
- $30.1M
- Operating income
- -$29.2M
- Income tax
- -$2.6M
- Net income
- -$30.6M
- EPS (basic)
- $-1.04
- EPS (diluted)
- $-1.04
Balance sheet
- Total assets
- $114.1M
- Current assets
- $56.7M
- Total liabilities
- $15.7M
- Current liabilities
- $11.6M
- Shareholders’ equity
- $98.4M
Cash flow
- Operating cash flow
- -$18.9M
- Investing cash flow
- $44.0M
- Financing cash flow
- $24.8M
- Net cash flow
- $50.1M
Statements via Polygon.io (SEC filings)
- Market cap
- $80.6M
- EPS (diluted)
- $-1.04
- Dividend yield
- 4.96%
- Shares outstanding
- 49.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 6, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $30.5M in FY2025.
- Revenue declined 77% from FY2021 to FY2025.
- Trading 43% below its 52-week high.
- Pays a dividend yielding about 4.96% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Rafael Holdings, Inc..
Write a review
News about Rafael Holdings, Inc.
News & sentiment via Polygon.io
